GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TOT Biopharm International Co Ltd (HKSE:01875) » Definitions » Owner Earnings per Share (TTM)

TOT Biopharm International Co (HKSE:01875) Owner Earnings per Share (TTM) : -0.17 (As of Dec. 2024)


View and export this data going back to 2019. Start your Free Trial

What is TOT Biopharm International Co Owner Earnings per Share (TTM)?

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

TOT Biopharm International Co's Owner Earnings per Share (TTM) ended in Dec. 2024 was HK$-0.17. It's Price-to-Owner-Earnings ratio for today is 0.


The historical rank and industry rank for TOT Biopharm International Co's Owner Earnings per Share (TTM) or its related term are showing as below:



HKSE:01875's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 30.5
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

TOT Biopharm International Co's Earnings per Share (Diluted) for the six months ended in Jun. 2024 was HK$0.04. Its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 was HK$0.05. It's PE Ratio (TTM) ratio for today is 35.19.

TOT Biopharm International Co's EPS without NRI for the six months ended in Jun. 2024 was HK$0.03. Its EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2024 was HK$0.04. It's PE Ratio without NRI ratio for today is 44.19.


TOT Biopharm International Co Owner Earnings per Share (TTM) Historical Data

The historical data trend for TOT Biopharm International Co's Owner Earnings per Share (TTM) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TOT Biopharm International Co Owner Earnings per Share (TTM) Chart

TOT Biopharm International Co Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Owner Earnings per Share (TTM)
Get a 7-Day Free Trial - -0.54 -0.13 -0.17 -

TOT Biopharm International Co Semi-Annual Data
Dec17 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Owner Earnings per Share (TTM) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.13 - -0.17 - -

Competitive Comparison of TOT Biopharm International Co's Owner Earnings per Share (TTM)

For the Biotechnology subindustry, TOT Biopharm International Co's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


TOT Biopharm International Co's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TOT Biopharm International Co's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where TOT Biopharm International Co's Price-to-Owner-Earnings falls into.


;
;

TOT Biopharm International Co Owner Earnings per Share (TTM) Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

To make it simple, then you will have:

Owner Earnings per Share (TTM) = (Net Income + Depreciation, Depletion and Amortization + Change In Deferred Tax - 5Y Average of Maintenance Capital Expenditure + Change In Working Capital) / Shares Outstanding (Diluted Average)

TOT Biopharm International Co's Owner Earnings per Share (TTM) Calculation:

Last Year Average of Last 5 Years
Net Income 37
Depreciation, Depletion and Amortization 0
Change In Deferred Tax 0
5Y Average of Maintenance Capital Expenditure 164
Change In Working Capital 0
Shares Outstanding (Diluted Average) 725

1. Start with "Net Income" from income statement. TOT Biopharm International Co's Net Income for the trailing twelve months (TTM) ended in Dec. 2024 was HK$37 Mil.

2. "Depreciation, Depletion and Amortization" is from cashflow statement. TOT Biopharm International Co's Depreciation, Depletion and Amortization for the trailing twelve months (TTM) ended in Dec. 2024 was HK$0 Mil. This needs to be added back because company does not actually need to pay cash for it. It is a non-cash item.

3. Other non-cash charges usually include "Stock Based Compensation" and "Change In Deferred Tax":
However, to be conservative, GuruFocus will not add Stock Based Compensation back to net income. TOT Biopharm International Co's Change In Deferred Tax for the trailing twelve months (TTM) ended in Dec. 2024 was HK$0 Mil.

4. Average maintenance capital expenditure over a business/industry cycle: 5-Year Average Maintenance Capital Expenditure = HK$164 Mil

It is usually best to take a long-term average of maintenance capital expenditure. Ideally this would be as long as 10 years and include at least one economic downturn. However, since many companies do not have as long as 10-year history, here GuruFocus uses the latest 5 years data to do the calculation. To smooth out unusual years but reflect recent developments, we take an average of the 5 year maintenance capital expenditure.

The following shows how to get maintenance capital expenditure.

First, calculate the revenue change regarding to the previous year. If the revenue decreased from the previous year, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
Second, if the revenue increased from the previous year, then calculate the percentage of Net PPE as of corresponding Revenue.
Growth Capital Expenditure = Percentage of Property, Plant and Equipment as of corresponding Revenue * Revenue Increase
Third, calculate Capital Expenditure (positive) - Growth Capital Expenditure.
If [Capital Expenditure (positive) - Growth Capital Expenditure] was negative, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
If [Capital Expenditure (positive) - Growth Capital Expenditure] was positive, then the Maintenance Capital Expenditure = Capital Expenditure (positive) - Growth Capital Expenditure.
Fourth, get the average of the 5 years maintenance capital expenditure.

TOT Biopharm International Co's 5-Year Average Maintenance Capital Expenditure = HK$164 Mil

5. "Change In Working Capital" is from cashflow statement. TOT Biopharm International Co's Change In Working Capital for the trailing twelve months (TTM) ended in Dec. 2024 was HK$0 Mil.
Note: GuruFocus' Change in Working Capital is provided by Morningstar. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement from original financial report. And sometimes it includes non-current parts of assets and liabilities.

6. TOT Biopharm International Co's Shares Outstanding (Diluted Average) for the months ended in Dec. 2024 was 725.197 Mil.

TOT Biopharm International Co's Onwer Earnings Per Share for Dec. 2024 is calculated as:

Owner Earnings per Share (TTM)
=( Net Income+Depreciation, Depletion and Amortization+Change In Deferred Tax
=( 37.109 +0+0
-5Y Avg of Maintenance CAPEX+Change In Working Capital )/Shares Outstanding (Diluted Average)
-164.474+0)/725.197
=-0.17

Price-to-Owner-Earnings=Current Price/Owner Earnings per Share (TTM)
=1.90/-0.17
=0

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Assumption: Companies usually do not report maintenance capital expenditures and growth capital expenditures separately. Here we use estimated numbers and average them over 5 years. The method to estimate maintenance capital expenditures can be found in above part 4.

Note: GuruFocus' Change In Working Capital is provided by Morningstar. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement from original financial report. And it includes non-current parts of assets and liabilities.


TOT Biopharm International Co Owner Earnings per Share (TTM) Related Terms

Thank you for viewing the detailed overview of TOT Biopharm International Co's Owner Earnings per Share (TTM) provided by GuruFocus.com. Please click on the following links to see related term pages.


TOT Biopharm International Co Business Description

Traded in Other Exchanges
N/A
Address
120 Changyang Street, Suzhou Industrial Park, Suzhou, CHN, 215024
TOT Biopharm International Co Ltd is a clinical-stage biopharmaceutical company dedicated to developing and commercializing oncology drugs and therapies for patients and their families as well as medical professionals. It has a pipeline of oncology drug candidates, which include monoclonal antibodies (mAbs) and antibody-drug conjugates (ADCs). It generates revenues from Mainland China.
Executives
Center Laboratories, Inc. 2201 Interest of corporation controlled by you
Tricor Trust (hong Kong) Limited 2301 Trustee
Chengwei Evergreen Capital, Lp 2101 Beneficial owner
Center Laboratories Inc. 2101 Beneficial owner
Chengwei Evergreen Management, Llc 2201 Interest of corporation controlled by you
Suzhou Vivo Management Consulting Partnership (limited Partnership)
Vivo (suzhou) Health Industry Investment Fund (limited Partnership)
Vivo Capital Llc
Vivo Capital Viii, Llc
Vivo Capital Fund Viii, L.p.
Prime Success International Limited 2101 Beneficial owner
Advantech Capital Ii L.p.
Advantech Capital Ii Master Investment Limited
Advantech Capital Investment V Limited
Advantech Capital Partners Ii Limited

TOT Biopharm International Co Headlines

No Headlines